ProEn Therapeutics Inc. announced that it has received funding from new investor Kolmar Korea Holdings Co., Ltd. on March 5, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8,250 KRW | -1.08% | -0.84% | +4.43% |
Apr. 03 | Intercos clarifies its position in lawsuit over Kolmar and Intercos Korea | AN |
Mar. 21 | Kolmar Korea Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+4.43% | 223M | |
+11.32% | 7.78B | |
+1.64% | 7.38B | |
+10.50% | 6.52B | |
-6.69% | 3.67B | |
-13.51% | 3.44B | |
-10.10% | 1.17B | |
+8.34% | 934M | |
-41.81% | 879M | |
-19.81% | 836M |
- Stock Market
- Equities
- A024720 Stock
- News Kolmar Holdings Co.,Ltd.
- ProEn Therapeutics Inc. announced that it has received funding from Kolmar Korea Holdings Co., Ltd.